These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 30254402)
1. Biomarkers for hepatocellular carcinoma: What's new on the horizon? Ocker M World J Gastroenterol; 2018 Sep; 24(35):3974-3979. PubMed ID: 30254402 [TBL] [Abstract][Full Text] [Related]
2. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy. Du J; Zhang E; Huang Z Front Immunol; 2024; 15():1358306. PubMed ID: 38665910 [TBL] [Abstract][Full Text] [Related]
3. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. Sakai K; Takeda H; Nishijima N; Orito E; Joko K; Uchida Y; Izumi N; Nishio K; Osaki Y Oncotarget; 2015 Aug; 6(25):21636-44. PubMed ID: 26046304 [TBL] [Abstract][Full Text] [Related]
4. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. Rastogi A World J Gastroenterol; 2018 Sep; 24(35):4000-4013. PubMed ID: 30254404 [TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. Neureiter D; Stintzing S; Kiesslich T; Ocker M World J Gastroenterol; 2019 Jul; 25(25):3136-3150. PubMed ID: 31333307 [TBL] [Abstract][Full Text] [Related]
6. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? Marisi G; Cucchetti A; Ulivi P; Canale M; Cabibbo G; Solaini L; Foschi FG; De Matteis S; Ercolani G; Valgiusti M; Frassineti GL; Scartozzi M; Casadei Gardini A World J Gastroenterol; 2018 Sep; 24(36):4152-4163. PubMed ID: 30271080 [TBL] [Abstract][Full Text] [Related]
7. Role of liver biopsy in hepatocellular carcinoma. Di Tommaso L; Spadaccini M; Donadon M; Personeni N; Elamin A; Aghemo A; Lleo A World J Gastroenterol; 2019 Oct; 25(40):6041-6052. PubMed ID: 31686761 [TBL] [Abstract][Full Text] [Related]
8. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Rizzo A; Brandi G Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983 [TBL] [Abstract][Full Text] [Related]
9. Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells. Qiu MJ; He XX; Bi NR; Wang MM; Xiong ZF; Yang SL Clin Chim Acta; 2018 Oct; 485():103-105. PubMed ID: 29940148 [TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNAs in hepatocellular carcinoma: Potential roles and clinical implications. Niu ZS; Niu XJ; Wang WH World J Gastroenterol; 2017 Aug; 23(32):5860-5874. PubMed ID: 28932078 [TBL] [Abstract][Full Text] [Related]
13. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Liu J; Liu Y; Meng L; Liu K; Ji B Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705 [TBL] [Abstract][Full Text] [Related]
14. Next Generation of Preclinical Liver Cancer Models. Weber A; O'Connor T; Heikenwalder M Clin Cancer Res; 2015 Oct; 21(19):4254-6. PubMed ID: 26169964 [TBL] [Abstract][Full Text] [Related]
15. Biomarkers for response to immunotherapy in hepatobiliary malignancies. Lin ZF; Qin LX; Chen JH Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935 [TBL] [Abstract][Full Text] [Related]